ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy
{{output}}
Background and objective: Darolutamide is an androgen receptor inhibitor (ARI) with low blood-brain barrier penetration, potentially resulting in low reactive testosterone increases and less feminizing adverse events (AEs). In th... ...
